Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

Conditions:   Neuroendocrine Tumor;   Anaplastic Thyroid Cancer;   Adenocarcinoma;   Pheochromocytoma;   Paraganglioma Intervention:   Drug: Cabozantinib 40 mg Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   Ipsen;   Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials